Huons Co., Ltd.
Quick facts
Marketed products
- Restasis · Other
Phase 3 pipeline
- Botox Inj · Neurology, Dermatology, Aesthetics
Botox (botulinum toxin type A) blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. - HA 0.3% · Ophthalmology or Dermatology
HA 0.3% is a hyaluronic acid-based topical or injectable formulation that provides hydration, lubrication, and tissue support through its viscoelastic properties. - HE 10
HE 10 is a therapeutic agent in development by Huons Co., Ltd., currently in phase 3 clinical trials. - High hyal Plus inj. · Orthopedics / Dermatology
High hyal Plus is a hyaluronic acid-based injectable that provides viscoelastic supplementation and tissue hydration for joint or dermatological applications. - HU-014 · Oncology
HU-014 is a synthetic oligonucleotide that acts as a telomerase inhibitor. - HU-014 Inj · Diabetes
HU-014 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. - HU007 · Diabetes
HU007 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. - HUC3-637
HUC3-637 is an investigational drug with unknown mechanism of action. - HUC3-637-R
HUC3-637-R's mechanism of action is currently unknown. - Humia inj. · Oncology / General (adjuvant for drug delivery)
Humia is a recombinant human hyaluronidase injection designed to enhance tissue permeability and facilitate drug distribution. - Hutox Inj · Aesthetics, Neurology
Hutox is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions. - Hyalein Mini Eye Drops · Ophthalmology
Hyalein Mini Eye Drops is a hyaluronic acid-based lubricating eye drop that provides moisture and protection to the ocular surface. - Moisview · Other
- Moisview Eye drop · Ophthalmology
Moisview is an eye drop formulation designed to treat dry eye disease by providing ocular surface lubrication and potentially reducing inflammation. - Restasis eye drop · Ophthalmology
Restasis (cyclosporine) suppresses T-cell activation and reduces inflammatory cytokine production in the lacrimal glands and ocular surface to increase tear production.
Phase 2 pipeline
Phase 1 pipeline
- Besylsartan · Other
- HUC2-344
- HUC2-344-R1, HUC2-344-R2
- HUC2-565-A, HUC2-565-A and HUC2-565-B
- HUC2-565-B, HUC2-565-A and HUC2-565-B
- HUC2-676
- HUC2-676-R
- HUG186
- HUG186-B and HUG186-D
- NCP112
- RDG-17012 Capsule
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: